Recruiting

Testing a fast-acting blood pressure medication for brain bleeding

Plain-English translation of NCT06402968 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

What is this trial?

This trial is testing clevidipine, a fast-acting intravenous medication that lowers blood pressure. The study compares how well this medication works compared to other standard blood pressure-lowering treatments in people who have had a sudden brain bleed with high blood pressure. Researchers want to know if the medication can bring blood pressure under control more quickly and safely within the first hour of treatment.

When someone has a brain bleed, very high blood pressure can make the bleeding worse and cause more damage to the brain. Doctors need medications that work quickly and reliably to bring blood pressure down safely. This trial will help determine if the medication offers a faster or safer way to do this compared to current standard treatments.

Do you qualify?

You likely qualify if…

you are 18 years old or older but younger than 100
you have been diagnosed with a brain bleed (intracerebral hemorrhage) and can start treatment within 12 hours of symptom onset
you show signs of stroke, such as weakness, speech problems, or vision changes
your blood pressure is between 150 and 220 mmHg when measured twice, 5–10 minutes apart
you are able and willing to complete follow-up visits at 90 and 180 days after enrollment

You likely don't qualify if…

the exact time your symptoms started cannot be determined
you have a known brain tumor, abnormal blood vessels, or aneurysm in your brain
your initial blood pressure is 220 mmHg or higher
you are unable to provide informed consent or have no legally authorized representative available

What participation looks like

If you qualify, you will be treated at one of the participating hospitals. You will receive either clevidipine or another standard blood pressure medication intravenously (through an IV). The medical team will closely monitor your blood pressure and brain function over the first hour and beyond. You will have follow-up appointments at 90 days and 180 days after your initial treatment to assess your recovery and any long-term outcomes.

AI-generated summary from trial data · Jul 11, 2026 · Not medical advice

Trial locations(18 sites)

United States

University of California, Irvine, California

Antelope Valley Medical Center, Lancaster, California

Stanford Medical Center (Stanford Health Care), Palo Alto, California

Cleveland Clinic Martin North Hospital, Stuart, Florida

University of South Florida, Tampa, Florida